“My studies in this area lead me to a very uncomfortable conclusion: Our citizens would be far better off if we removed all the psychotropic drugs from the market, as doctors are unable to handle them. It is inescapable that their availability creates more harm than good.” — Peter Gøtzsche
I am probably still many years away of having the credentials of Peter Gøtzsche. Moreover, I don’t think that I can even get close to the reputability earned by Peter (even if I decide to continue working hard on biomedical research during the next years or probably decades). Dr. Gøtzsche sets a very high standard for critics of the drug industry as Richard Smith (former editor of The BMJ) already pointed out.
…“Critics of the drug industry have been increasing in number, respectability, and vehemence, and Peter has surpassed them all in comparing the industry with organised crime.”…
Nonetheless, right now I would like to declare that my research on psychiatric drugs (independent research) supports the statements of Peter C. Gøtzsche (1-8).
- Ramirez, Jorge H (2014): Clasificación antidepresivos y antipsicoticos. figshare.http://dx.doi.org/10.6084/m9.figshare.1184484
- Ramirez, Jorge H (2014): Database of human studies evaluating antidepressant drugs. figshare.
- Re: Putting GlaxoSmithKline to the test over paroxetine. The BMJ.
- Ramirez, Jorge H (2014): Duloxetine database | WHO ICTRP, ClinicalTrials.gov, Embase, PubMed, ISI, others. figshare.http://dx.doi.org/10.6084/m9.figshare.1096304
- Ramirez, Jorge H (2014): Agomelatine (Valdoxan) – Over 80% registered studies of this antidepressant drug are unpublished. figshare. http://dx.doi.org/10.6084/m9.figshare.1126326
- Ramirez, Jorge H (2014): Paroxetine: analysis of unpublished human studies (observationals and clinical trials). figshare. http://dx.doi.org/10.6084/m9.figshare.1103284
- The meta-analysis of published and unpublished studies of agomelatine is misleading. The BMJ.